Month: January 2025

SAN MATEO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) will announce its financial results for the fourth quarter and full year ended December 31, 2024 following the close of market on Tuesday, February 11, 2025. Freshworks will host a live audio webcast beginning at 2:00 p.m Pacific Time / 5:00 p.m. Eastern Time that same day to discuss the company’s financial results and business highlights. Event: Freshworks Fourth Quarter and Full Year 2024 Financial Results Date: Tuesday, February 11, 2025Time: 2:00 p.m. PT / 5:00 p.m. ETAudio webcast: https://ir.freshworks.com A webcast replay will be accessible from the Freshworks investor relations website at https://ir.freshworks.com. The press release will be accessible from the Freshworks investor relations website prior to the commencement of the event. About...

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time. To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing visibility around women’s health. SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced today that Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will be speaking on the ARPA-H | Investing in Women’s Health panel during the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The panel will be on Tuesday, January 14th at 2:15 p.m. PT and will be followed by two additional panels focused on women’s health, The Future of Women’s Health Care and Flow of Capital...

FREMONT, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced that it is expanding in Latin America with the launch of IQ8P™ Microinverters, with peak output AC power of 480 W, for residential and commercial applications in Colombia, Panama, and Costa Rica to support newer high-powered solar modules. Enphase is working with installers and distributors throughout Latin America, including the recent launch of IQ8™ Microinverters in the Caribbean, as well as ongoing operations in Brazil, Puerto Rico, and Mexico. IQ8 Microinverters are designed to maximize energy production and can manage a continuous DC current of 14 amperes, supporting higher-powered solar...

Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025 NEWTON, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the Journal of Prevention of Alzheimer’s Disease...

Addition of experienced bankers in the DMV region complements EagleBank’s C&I growth strategy BETHESDA, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) — EagleBank (NASDAQ: EGBN), one of the largest community banks in the Washington, D.C. area, today announced that Bryan Pynchon will join the Bank as a C&I Market Executive for Maryland and Ian Joseph and Andrew Brkic as Relationship Managers (RMs) under Pynchon’s leadership, as of January 6, 2025. In their respective roles, the new team members will work to advance EagleBank’s goal of expanding its robust, diverse, and stable C&I portfolio. “The talent that we put in front of clients is a point of pride for Eagle and adding Bryan, Ian and Andrew to the team will even further enhance our position as the go-to commercial lender in the Greater Washington community,” said Evelyn...

– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center.Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion...

TARRYTOWN, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 third quarter earnings release on Thursday, February 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. A conference call replay will be available for approximately one week following completion of the live call and can be accessed...

PHOENIX, Jan. 09, 2025 (GLOBE NEWSWIRE) — WillScot Holdings Corp. (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative flexible space solutions, announced today that the Company will host an investor day on March 7, 2025. The event will take place in Phoenix, Arizona and begin at 9:00 a.m. MST. Invitations will be distributed to investors at a later date. The Company is also reaffirming its most recently stated Fiscal Year 2024 guidance. About WillScot Listed on the Nasdaq stock exchange under the ticker symbol “WSC,” WillScot is the premier provider of highly innovative and turnkey space solutions in North America. The Company’s comprehensive range of products includes modular office complexes, mobile offices, classrooms, temporary restrooms, portable storage containers, protective buildings and climate-controlled...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company“) is pleased to announce that it intends to complete a non-brokered private placement of unsecured convertible debentures of the Company (the “Convertible Debentures”) in an aggregate amount of C$400,000 (the “Offering”). The Convertible Debentures will be sold in principal amounts of C$1,000 and will mature 12 months from the date of issuance (the “Maturity Date”). The Convertible Debentures will bear interest at a rate of 10% per annum, calculated quarterly in arrears and payable on the Maturity Date (as defined below). The principal amount of each Convertible Debenture,...